Inicio・Lista de Acciones・Genmab A-S

Genmab A-S

Cerrado

2,196 -0.81

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2177

Máximo

2231

Métricas clave
By Trading Economics
Ingresos	243M 295M
Ventas	259M 1.2B
P/B Media del Sector	26.175 56.659
BPA	34.85
Margen de beneficios	25.541
Empleados	3,119
EBITDA	216M 431M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	-1.49% downside

Dividendos
By Acuity
Próximas Ganancias	5 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	19B 132B
Apertura anterior	2196.81
Cierre anterior	2196

Genmab A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 sept 2026, 23:56 UTC

C.H. Robinson Worldwide shares are lower in after-market trading, despite a broader market rally amid reduced interest rate hike expectations.

3 sept 2026, 23:56 UTC

News

Missouri American Water acquired Neosho's water systems for $34.5 million, adding 5,400 customers. Shares of American Water Works traded higher in after-market hours.

3 sept 2026, 23:56 UTC

SiTime Corp shares are lower in after-market hours, continuing a decline that began earlier, despite gains in major indices.

3 sept 2026, 23:56 UTC

Elme Communities shares traded roughly flat in after-market hours. Broader market trends reflect gains in major averages amid reduced interest rate hike expectations.

3 sept 2026, 23:56 UTC

News

Correlated Moves

Paychex receives a buy rating on strong revenue growth and strategic AI integration. After-market trading has shown little change since Thursday's close.

3 sept 2026, 23:56 UTC

News

Jefferies initiated coverage on Nexgen Energy with a Buy rating and a C$21 price target. Shares moved higher in after-market hours.

3 sept 2026, 23:56 UTC

Tapestry Inc. shares rose slightly in after-market trading, reflecting broader market gains amid reduced interest rate hike expectations. They remain below their 20-day moving average.

3 sept 2026, 23:56 UTC

Loews Corp shares are higher in after-market hours, reflecting broader market gains amid reduced interest rate hike expectations.

3 sept 2026, 23:56 UTC

Union Pacific Corp shares are higher in after-market trading, following gains in major indices amid reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

3 sept 2026, 23:56 UTC

Sportsman's Warehouse shares advanced in after-market trading, reflecting broader market gains amid reduced expectations for an interest rate hike.

3 sept 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-hours trading, continuing a decline since Thursday's close, despite broader market gains. No specific news was identified.

3 sept 2026, 23:56 UTC

General Motors traded roughly flat after-market hours amid strong market momentum driven by reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

3 sept 2026, 23:56 UTC

Wingstop Inc shares are trading higher in after-market hours, supported by strong gains in major indices amid reduced interest rate hike expectations, according to CME Group.

3 sept 2026, 23:51 UTC

Exelon Corp shares are lower in after-market hours, diverging from broader market gains amid anticipation of upcoming employment data. No specific news was identified.

3 sept 2026, 23:51 UTC

Japan's Household Spending Falls 3.6% YoY in July, Marking Eighth Straight Month of Decline Amid Economic Uncertainty

3 sept 2026, 23:51 UTC

Japan's Household Spending MoM for July rises 0.5%, falling short of 2.6% expectations, raising concerns over consumer behavior amid a year-on-year decline of 3.6%.

3 sept 2026, 23:51 UTC

Canada's Ivey PMI forecasted to rise to 56.2 in August, signaling cautious optimism amid mixed business confidence trends and regional recovery signals.

3 sept 2026, 23:51 UTC

Iovance Biotherapeutics Inc shares are higher in after-market trading, maintaining a position above its 20-day moving average amid broader market gains.

3 sept 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

3 sept 2026, 23:51 UTC

News

Social Media

Dutch Bros Inc filed a mixed securities shelf registration, enabling potential issuance of various securities. Shares are trading higher in after-market hours.

3 sept 2026, 23:51 UTC

Yelp Inc shares are higher in after-market trading, following gains in the broader market. No specific company news was identified to explain the movement.

3 sept 2026, 23:51 UTC

News

Social Media

Tesla Inc. shares are lower in after-market trading following the invite-only launch event for its Cybercab in Austin, as details remain restricted.

3 sept 2026, 23:51 UTC

Shake Shack Inc shares are lower in after-market hours, continuing a downward trend below the 20-day moving average and nearing the one-month range low.

3 sept 2026, 23:46 UTC

Hilton Worldwide Holdings Inc shares are trading higher in after-market hours, supported by gains in major indices amid anticipation of Friday's employment report.

3 sept 2026, 23:46 UTC

Correlated Moves

Kimco Realty Corp shares are lower in after-market hours, reflecting a decline since Thursday's close. Broader market trends also show weakness.

3 sept 2026, 23:46 UTC

News

Weyerhaeuser Co remains about 4.95% below its 20-day moving average. Shares were roughly flat in after-market hours following a price target cut to $28.

3 sept 2026, 23:46 UTC

FedEx Corp shares are lower in after-market trading, reflecting a decline from Thursday's close. The stock showed initial strength before pulling back.

3 sept 2026, 23:46 UTC

Correlated Moves

AMETEK Inc. shares declined in after-market trading, reflecting broader small-cap market trends amid significant gains in major indices earlier in the session.

3 sept 2026, 23:46 UTC

Correlated Moves

Box Inc shares are lower in after-market hours following significant volatility. The decline may be linked to a drop in Asana Inc's stock.

3 sept 2026, 23:46 UTC

Marcus & Millichap shares are lower in after-market trading, despite broader market gains. No specific news was identified to explain the decline.

Comparación entre iguales

Cambio de precio

Genmab A-S previsión

Precio Objetivo

By TipRanks

-1.49% descenso

Estimación a 12 Meses

Media 2,493.35 DKK -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genmab A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Genmab A-S Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.